Point72 Hong Kong’s Third Harmonic Bio THRD Stock Holding History

Point72 Hong Kong’s Portfolio THRD Stock Details THRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-19,099	Closed	-$362K	–	1531
2022 Q3	$362K	Buy	+19,099	New	+$344K	0.01%	872

Other funds holding THRD

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Hong Kong's THRD Position: Q4 2022 in Review

Point72 Hong Kong sold out of Third Harmonic Bio (THRD) in Q4 2022, closing a stake of 19,099 shares — an estimated $362K sold.

Point72 Hong Kong first reported a position in THRD in Q3 2022 and held it in 1 quarter. The position peaked at $362K in Q3 2022. 50 funds tracked by Wall St. Rank hold THRD as of Q4 2022.

Point72 Hong Kong reported no remaining Third Harmonic Bio position as of Q4 2022 after selling out during the quarter.
Point72 Hong Kong sold 19,099 Third Harmonic Bio shares in Q4 2022, an estimated $362K.
Point72 Hong Kong first reported a position in Third Harmonic Bio in Q3 2022 and held it in 1 quarter.
Point72 Hong Kong's Third Harmonic Bio position peaked at $362K in Q3 2022.
50 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.